The task of this Core is to provide well characterized, high-quality human-derived biospecimens required by the projects and to insure that longitudinal, structured, clinical information related to treatment and outcome is collected from the patient donors of those specimens. The primary substrate for these genetic characterization projects is a unique resource consisting of whole-organ maps that will provide histologic characterization and sufficient DNA and RNA to allow multiple experiments to be done on the same samples. This provides an unprecedented opportunity to cross-validate biologic insights coming from these different experimental platforms, and should provide, by far, the most complete view of urothelial carcinogenesis and progression ever realized. This Core will serve as a model for addressing the difficult problems of cross investigator and cross-institutional data exchange, issues of significant interest for the broader context of Texas cancer research. This Core will provide a web-based portal that will allow all investigators to browse and query the contents of the biorepository, de-identified clinical data, and translational research resources such as Standard Operating Procedures, reagent details, and primary datasets.
The specific aims for the core are as follows:
Specific Aim 1 : Provide pathologic review of all tissues.
Specific Aim 2 : Maintain a urothelial biospecimen repository, Specific Aim 3: Provide professional and technical services for the preparation and quality control of molecular analytes from the biospecimen repository.
Specific Aim 4 : Abstract clinical information for all patients providing biospecimens.
Specific Aim 5 : Capture longitudinal clinical follow-up on all patients providing biospecimens.
Specific Aim 6 : Assure that all information related to the SPORE Project is exchangeable.
Specific Aim 7 : Provide all SPORE Investigators with a common portal for access to Project data, including support for ad hoc query across projects and domains
The projects of this SPORE will use human cancer bladder specimens and human bladder cancer cell lines for translational research directed toward improving the detection, prevention, and treatment of human bladder cancer. The Core will provide the investigators at The University of Texas MD Anderson Cancer Center as well as other collaborating institutions with high quality tissue samples from patients with bladder cancer diagnosed, treated, and followed in our institution. Standardized and centralized procedures have been established for tissue procurement, quality control, processing, storage, and distribution of samples to individual investigators. They will ensure optimal utilization of the samples according to the guidelines established by the Tissue Committee and IRB regulations.
|Choi, Woonyoung; Porten, Sima; Kim, Seungchan et al. (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152-65|
|Hoang, Anthony N; Agarwal, Piyush K; Walton-Diaz, Annerleim et al. (2014) Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int 113:E28-33|
|Benedict, W F; Fisher, M; Zhang, X-Q et al. (2014) Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFN?/Syn3 treatment in a phase l study. Cancer Gene Ther 21:91-4|
|Figueroa, Jonine D; Ye, Yuanqing; Siddiq, Afshan et al. (2014) Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 23:1387-98|
|Culp, Stephen H; Dickstein, Rian J; Grossman, H Barton et al. (2014) Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191:40-7|
|Chakravarti, Deepavali; Su, Xiaohua; Cho, Min Soon et al. (2014) Induced multipotency in adult keratinocytes through down-regulation of ?Np63 or DGCR8. Proc Natl Acad Sci U S A 111:E572-81|
|Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-22|
|Dinney, Colin P N; Hansel, Donna; McConkey, David et al. (2014) Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol 32:1108-15|
|Yan, Chao; Liu, Degang; Li, Liwei et al. (2014) Discovery and characterization of small molecules that target the GTPase Ral. Nature 515:443-7|
|Lee, Eugene K; Ye, Yuanquing; Kamat, Ashish M et al. (2013) Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer 119:1643-51|
Showing the most recent 10 out of 178 publications